Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Eli Samaha Sells 37,799 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00. Following the transaction, the insider owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This represents a 0.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Eli Samaha also recently made the following trade(s):

• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.13, for a total transaction of $428,712.51.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Down 0.1%

TBPH opened at $16.98 on Thursday. The company has a market capitalization of $875.37 million, a PE ratio of 7.72 and a beta of 0.17. The firm has a 50-day simple moving average of $16.56 and a two-hundred day simple moving average of $17.29. Theravance Biopharma, Inc. has a 52 week low of $10.82 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, sell-side analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. TD Cowen increased their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. Finally, B. Riley Financial lifted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $21.40.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new stake in shares of Theravance Biopharma in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its holdings in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC raised its position in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.